Cargando…

ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Purpose: To develop a qPCR method to examine the 202 isoform of excision repair cross-complementation group 1 (ERCC1_202) and to evaluate its clinical utility as a predictive biomarker for platinum-based chemotherapy in non-small cell lung cancer (NSCLC). Methods: The relative complementary DNA (cDN...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiyong, Zhu, Xiaoli, Zhang, Hongming, Fan, Xiaobo, Xue, Xiulei, Chen, Yan, Ding, Chenbo, Zhao, Jianwen, Wu, Guoqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604217/
https://www.ncbi.nlm.nih.gov/pubmed/28928874
http://dx.doi.org/10.7150/jca.19897
_version_ 1783264831358369792
author Wang, Xiyong
Zhu, Xiaoli
Zhang, Hongming
Fan, Xiaobo
Xue, Xiulei
Chen, Yan
Ding, Chenbo
Zhao, Jianwen
Wu, Guoqiu
author_facet Wang, Xiyong
Zhu, Xiaoli
Zhang, Hongming
Fan, Xiaobo
Xue, Xiulei
Chen, Yan
Ding, Chenbo
Zhao, Jianwen
Wu, Guoqiu
author_sort Wang, Xiyong
collection PubMed
description Purpose: To develop a qPCR method to examine the 202 isoform of excision repair cross-complementation group 1 (ERCC1_202) and to evaluate its clinical utility as a predictive biomarker for platinum-based chemotherapy in non-small cell lung cancer (NSCLC). Methods: The relative complementary DNA (cDNA) quantification for ERCC1_202 was conducted using a fluorescence-based, real-time detection method and β-actin was used as a reference gene. Results: A strong correlation was observed between ERCC1_202 mRNA and ERCC1 mRNA levels in NSCLC cells (P < 0.001). 28 patients completed this research. Our results implied that as ERCC1_202 levels increased, the risk of progression (HR = 4.296, P = 0.011) and death (HR = 6.503, P = 0.001) increased. At multivariate analysis, high expression of ERCC1_202 was shown to be an independent predictive factor for time to progression (P = 0.047), and progression-free survival (P = 0.014). However, the high expression of ERCC1_202 was not an independent predictive factor for response (P = 0.324). Conclusions: This study suggests that the efficacy of platinum-based chemotherapy can be improved when customized according to the expression of ERCC1_202.
format Online
Article
Text
id pubmed-5604217
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-56042172017-09-19 ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy Wang, Xiyong Zhu, Xiaoli Zhang, Hongming Fan, Xiaobo Xue, Xiulei Chen, Yan Ding, Chenbo Zhao, Jianwen Wu, Guoqiu J Cancer Research Paper Purpose: To develop a qPCR method to examine the 202 isoform of excision repair cross-complementation group 1 (ERCC1_202) and to evaluate its clinical utility as a predictive biomarker for platinum-based chemotherapy in non-small cell lung cancer (NSCLC). Methods: The relative complementary DNA (cDNA) quantification for ERCC1_202 was conducted using a fluorescence-based, real-time detection method and β-actin was used as a reference gene. Results: A strong correlation was observed between ERCC1_202 mRNA and ERCC1 mRNA levels in NSCLC cells (P < 0.001). 28 patients completed this research. Our results implied that as ERCC1_202 levels increased, the risk of progression (HR = 4.296, P = 0.011) and death (HR = 6.503, P = 0.001) increased. At multivariate analysis, high expression of ERCC1_202 was shown to be an independent predictive factor for time to progression (P = 0.047), and progression-free survival (P = 0.014). However, the high expression of ERCC1_202 was not an independent predictive factor for response (P = 0.324). Conclusions: This study suggests that the efficacy of platinum-based chemotherapy can be improved when customized according to the expression of ERCC1_202. Ivyspring International Publisher 2017-08-23 /pmc/articles/PMC5604217/ /pubmed/28928874 http://dx.doi.org/10.7150/jca.19897 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Wang, Xiyong
Zhu, Xiaoli
Zhang, Hongming
Fan, Xiaobo
Xue, Xiulei
Chen, Yan
Ding, Chenbo
Zhao, Jianwen
Wu, Guoqiu
ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
title ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
title_full ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
title_fullStr ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
title_full_unstemmed ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
title_short ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
title_sort ercc1_202 is a prognostic biomarker in advanced stage non-small cell lung cancer patients treated with platinum-based chemotherapy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604217/
https://www.ncbi.nlm.nih.gov/pubmed/28928874
http://dx.doi.org/10.7150/jca.19897
work_keys_str_mv AT wangxiyong ercc1202isaprognosticbiomarkerinadvancedstagenonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT zhuxiaoli ercc1202isaprognosticbiomarkerinadvancedstagenonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT zhanghongming ercc1202isaprognosticbiomarkerinadvancedstagenonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT fanxiaobo ercc1202isaprognosticbiomarkerinadvancedstagenonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT xuexiulei ercc1202isaprognosticbiomarkerinadvancedstagenonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT chenyan ercc1202isaprognosticbiomarkerinadvancedstagenonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT dingchenbo ercc1202isaprognosticbiomarkerinadvancedstagenonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT zhaojianwen ercc1202isaprognosticbiomarkerinadvancedstagenonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT wuguoqiu ercc1202isaprognosticbiomarkerinadvancedstagenonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy